The global phenobarbital market is set to reach a valuation of $2.23B by 2030, from $1.58B in 2023, reflecting a CAGR of 5%, according to a report by Research & Markets.
Phenobarbital boasts a track record of managing epilepsy and seizure disorders, positioning it as a frontline treatment option, particularly in regions with limited healthcare resources. The drug's capacity to efficiently halt seizures bolsters its demand and utilization within the market.
Nonetheless, the phenobarbital market faces challenges from substitute antiepileptic medications boasting improved safety profiles and fewer adverse effects. The advent of novel drugs with distinct mechanisms of action and targeted indications has expanded the range of alternatives for treating epilepsy and seizure disorders. This broadened selection empowers healthcare practitioners to opt for newer medications when minimizing adverse effects or drug interactions becomes a priority.